HomeScience & DiscoveryResearch & DevelopmentClinical DevelopmentPublicationsProductsTeamNews and EventsCareersContact Us

Senior Scientist - Dr. William Campbell, Ph.D.
Dr. Campbell has over 30 year of experience in the field of protein chemistry. In 1989, while in Japan as an associate professor at Nagoya City University he discovered a novel enzyme, carboxypeptidase R, an important regulator of inflammation and fibrinolysis. Over the past several years he has made use of novel computer algorithms that create peptide antibody mimetics to targets in proteins and has used peptide array technology to identify potential drug candidates for both therapeutic and diagnostic applications. After leaving Japan, Dr. Campbell spent two years as visiting scientist at the Kinsmen Laboratory of Neurological Research at the University of British Columbia before joining Panagin.

Joshua Yu, Ph.D, Synthetic Chemistry Scientist
Dr. Joshua Yu received his doctoral degree from the University of Göttingen, Germany.  He continued his post-doctoral research in the University of British Columbia (UBC), Canada.  Dr. Yu has over 20 years of research experience in extraction and purification of active phytomedicinal compounds from herbs, modification of structure of the active molecules from herbs, and synthesis of small molecule compounds, Bioinorganic Chemistry, Organometallics and Nano-Cluster material Chemistry.  Dr. Yu has published over 20 academic papers on various world renowned journals and magazines and had applied several technology patents.

Guosong Qiu, M.D., Ph.D, Project Manager
Dr. Guosong Qiu graduated from the School of Medicine, Zhejiang University with a Bachelor of Medicine, and a Master of Science degree in Cardiovascular. In Canada, Dr. Qiu received his doctoral degree in Pathology and Laboratory Medicine at the University of British Columbia. Specializing in the clinical non-invasive and interventional diagnosis and research of cardiovascular medicine, Dr. Qiu holds a membership of the Canadian Society of Atherosclerosis, Thrombosis, and Vascular Biology (CSATVB). Dr. Qiu has profound knowledge in the mechanism of atherogenesis and development of coronary heart disease, and also utilizes lentivirus to mediate RNA interference to investigate the gene functions. He also conducted in-depth research on the non-lipid lowering effects of statins.

Sherman Zhao, MD, Ph.D, Clinical Project Manager
Dr. Sherman Zhao graduated from the Shanghai Medical University with a bachelor's degree in laboratory medicine.  At the Peking University, he received his doctoral degree in Pharmacology.  When Dr. Zhao was later studying in the Georgia State University, United States, he completed his post-doctoral research.  Prior to joining Pegasus, Dr. Zhao has gained profound knowledge and clinical experience in treating cancer and Alzheimer’s disease and has published over 10 papers.  He has also been engaged in the research and development of novel drugs in domestic and foreign pharmaceutical companies.  Dr. Zhao was the key person involved in the development of two phytopharmaceuticals which were approved for clinical trial in 2005, and is the principal investigator of the undergoing Phase III clinical trial.

Martin Wang, Ph.D, Regulatory Affair Project Manager
Dr. Wang has been actively involved in the research and development of phytopharmaceuticals and nutraceutical products in the past 20 years. Prior to joining Pegasus Pharmaceutical Group Inc., he was a Research Associate in the Cross Cancer Institute, University of Alberta, Canada and had been mainly focusing on the research of the efficacy of nano drugs on lung cancer. Later as a Senior Analyst in the Division of Food and Natural Health Product (NHP), ALS Laboratory Group, Edmonton, Canada, Dr. Wang had been analyzing the active ingredients and nutrition in food and NHP. Before coming to Canada, Dr. Wang was an Associate Professor in the School of Pharmacy, Nanjing University of Traditional Chinese Medicine, China. Concurrently he also served as the Deputy Director of the Jiangsu Provincial Centre for Quality Control of Chinese Medicine. Dr. Wang has extensive experience in novel drug research from screening natural products as drug candidates to translational studies of investigational drugs as well as formulation, pilot-scale development, chromatographic fingerprinting profiles of finished botanical products, and quality control. He also has years of regulatory affairs experience with strong knowledge in the licensing of Canada NHP and US FDA botanical drug IND or food supplement as well as China SFDA novel drug applications. In 1997, Dr. Wang received his doctoral degree from the Nanjing University of Traditional Chinese Medicine, China. He finished his post-doctoral research in the Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Japan and then in Jinling Pharmaceutical Company, Nanjing, China. Dr. Wang has over 50 publications in peer-reviewed journals and 3 patents of novel botanical drugs in China. He joined Pegasus Pharmaceuticals Group Inc. in 2007 and is currently in charge of regulatory affairs.

Dr. James Goldie, MD, FRCPC
Dr. Goldie is Clinical Emeritus Professor at University of British Columbia, former Head of Medical Oncology of BC Cancer Agency. Dr. Goldie is a global leader in oncology, especially in the field of drug resistant cancer treatment and research. His theory (Goldie-Coldman Hypothesis) on cancer drug resistance is quoted in almost all of today's major oncology textbooks.  Dr. Goldie has more than 200 peer-reviewed publications and 29 textbook or chapters to his credit in the area of oncology.  Dr. Goldie advises PanaGin on clinical strategies and clinical trial protocol development.

Dr. Francis Law, Ph.D.
Dr. Francis Law is currently a Professor in the Department of Biological Sciences at Simon Fraser University. Dr. Francis Law's research interests include preclinical and clinical studies on safety and efficacy of biopharmaceuticals, nutraceuticals and natural health products especially Chinese herbal medicine; pharmacokinetic studies using laboratory animals and humans; application of classical and physiologically based pharmacokinetic(PBPK) models in herb research and development; in vitro prediction of drug/herb interactions using human liver microsomes and Caco-2 cells; analysis of active herbal components using GC/MS and HPLC/MS/MS; registration submission to Health Canada and US Food and Drug Administration for drugs and herbal products; environmental risk assessment of new drug and herbal products; and GLP, GCP and GMP compliance.

Dr. David Osoba, MD, FRCPC
Dr. David Osoba was a Professor of Medicine (Retired) at the University of British Columbia, and former Vice-President of the British Columbia Cancer Agency. With clinical background in medical oncology, Dr. David Osoba has research experience in immunology, clinical trials and quality-of-life measurement. For the past 17 years, he has been a member of the Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada (Chair from 1986-1996) and a member of the Board of Directors and immediate past president of the International Society for Quality of Life research (ISOQOL). Also, he was an Associate Editor of Quality of Life Research from its inception in 1992 until 2001. Dr. Osoba has more than 250 scientific publications to his credit. Dr. Osoba advises Panagin on clinical trial protocol development and data review.

Mr. Winter Huang, Chairman
Mr. Huang is a versatile entrepreneur with many years of experience in a variety of business fields and has a keen interest in the development of cutting-edge biotechnology. Mr. Huang is the principal inventor of Panagin's core patents.

Mr. Victor Ding, MBA
Mr. Ding, a seasoned financial manager, is a co-founder of Panagin.

Copyright © 2002-2010 Panagin Pharmaceuticals Inc. All rights reserved.
中文 English